These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22238444)

  • 21. Evaluation of Cycle Threshold, Toxin Concentration, and Clinical Characteristics of Clostridioides difficile Infection in Patients with Discordant Diagnostic Test Results.
    Shah MD; Balada-Llasat JM; Coe K; Reed E; Sandlund J; Pancholi P
    J Clin Microbiol; 2020 Apr; 58(5):. PubMed ID: 32051264
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of two commercial molecular assays to a laboratory-developed molecular assay for diagnosis of Clostridium difficile infection.
    Karre T; Sloan L; Patel R; Mandrekar J; Rosenblatt J
    J Clin Microbiol; 2011 Feb; 49(2):725-7. PubMed ID: 21123537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Environmental shedding of toxigenic Clostridioides difficile by asymptomatic carriers: A prospective observational study.
    Gilboa M; Houri-Levi E; Cohen C; Tal I; Rubin C; Feld-Simon O; Brom A; Eden-Friedman Y; Segal S; Rahav G; Regev-Yochay G;
    Clin Microbiol Infect; 2020 Aug; 26(8):1052-1057. PubMed ID: 31904567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of BD GeneOhm Cdiff and Seegene Seeplex ACE PCR assays using toxigenic Clostridium difficile culture for direct detection of tcdB from stool specimens.
    Shin BM; Mun SJ; Yoo SJ; Kuak EY
    J Clin Microbiol; 2012 Nov; 50(11):3765-7. PubMed ID: 22952270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid detection assay of toxigenic Clostridioides difficile through PathOC RightGene, a novel high-speed polymerase chain reaction device.
    Okanda T; Mitsutake H; Aso R; Sekizawa R; Takemura H; Matsumoto T; Nakamura S
    Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115247. PubMed ID: 33188946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence, characteristics and antimicrobial susceptibility patterns of Clostridioides difficile isolated from hospitals in Iran.
    Alimolaei M; Rahimi HR; Ezatkhah M; Shamsaddini Bafti M; Afzali S
    J Glob Antimicrob Resist; 2019 Dec; 19():22-27. PubMed ID: 30825696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era.
    Polage CR; Gyorke CE; Kennedy MA; Leslie JL; Chin DL; Wang S; Nguyen HH; Huang B; Tang YW; Lee LW; Kim K; Taylor S; Romano PS; Panacek EA; Goodell PB; Solnick JV; Cohen SH
    JAMA Intern Med; 2015 Nov; 175(11):1792-801. PubMed ID: 26348734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clostridioides difficile laboratory diagnostic techniques: a comparative approach of rapid and molecular methods.
    Camargo TS; Junior MS; Camargo LFA; Biotto VP; Doi AM; Koga PCM; França CN; Martino MDV
    Arch Microbiol; 2021 May; 203(4):1683-1690. PubMed ID: 33459815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The use of two-stage algorithm in the diagnosis of patients with low levels of Clostridium difficile toxins A/B in feces confirmed by using enzyme immunoassay].
    Nurzyńska G; Pituch H; Kamola R; Kopeć ES
    Med Dosw Mikrobiol; 2013; 65(4):263-8. PubMed ID: 24730214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Clinical and Laboratory Impact of Upgrading Clostridioides (formerly Clostridium) difficile Infection Testing from Routine to Molecular Based-Algorithm: an Observational Case-Study from the Eastern Province, Saudi Arabia.
    Alnimr A; Alwazzeh MJ; Al-Ameer A
    Clin Lab; 2019 Aug; 65(8):. PubMed ID: 31414736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk Factors that Predict Recurrent Clostridium difficile Infections in Surgical Patients.
    Messick CA; Hammel JP; Hull T
    Am Surg; 2017 Jun; 83(6):653-659. PubMed ID: 28637570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Risk Factors for Clostridium difficile Infection Based on Immunochromatography Testing and Toxigenic Culture Assay.
    Ohshima T; Osaki T; Yamamoto Y; Asai S; Miyachi H; Kamiya S
    J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30232129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid stool-based diagnosis of Clostridium difficile infection by real-time PCR in a children's hospital.
    Luna RA; Boyanton BL; Mehta S; Courtney EM; Webb CR; Revell PA; Versalovic J
    J Clin Microbiol; 2011 Mar; 49(3):851-7. PubMed ID: 21209161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of
    Senok AC; Aldosari KM; Alowaisheq RA; Abid OA; Alsuhaibani KA; Khan MA; Somily AM
    Saudi J Gastroenterol; 2017; 23(4):259-262. PubMed ID: 28721981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of real-time PCR techniques to cytotoxigenic culture methods for diagnosing Clostridium difficile infection.
    Knetsch CW; Bakker D; de Boer RF; Sanders I; Hofs S; Kooistra-Smid AM; Corver J; Eastwood K; Wilcox MH; Kuijper EJ
    J Clin Microbiol; 2011 Jan; 49(1):227-31. PubMed ID: 20980562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of a newly developed high-speed polymerase chain reaction analysis system for the diagnosis of Clostridioides difficile infection.
    Furukawa K; Mitsutake H; Aso R; Sekizawa R; Okanda T; Hayashi K; Matsumoto T; Nakamura S
    J Infect Chemother; 2021 May; 27(5):715-721. PubMed ID: 33402305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program.
    Longtin Y; Trottier S; Brochu G; Paquet-Bolduc B; Garenc C; Loungnarath V; Beaulieu C; Goulet D; Longtin J
    Clin Infect Dis; 2013 Jan; 56(1):67-73. PubMed ID: 23011147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular characterization of pathogenicity locus (PaLoc) and tcdC genetic diversity among tcdA
    Kodori M; Ghalavand Z; Yadegar A; Eslami G; Azimirad M; Krutova M; Abadi A; Zali MR
    Anaerobe; 2020 Dec; 66():102294. PubMed ID: 33181348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity.
    Humphries RM; Uslan DZ; Rubin Z
    J Clin Microbiol; 2013 Mar; 51(3):869-73. PubMed ID: 23269736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of fecal Clostridium difficile load in discrepancies between toxin tests and PCR: is quantitation the next step in C. difficile testing?
    Leslie JL; Cohen SH; Solnick JV; Polage CR
    Eur J Clin Microbiol Infect Dis; 2012 Dec; 31(12):3295-9. PubMed ID: 22814877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.